PC
BMRN icon

Pier Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pier Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-720
Closed -$52K – 137
2013
Q3 		$52K Hold
720
– – 0.01% 119
2013
Q2 		$40K Buy
+720
New +$44.9K 0.01% 122

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pier Capital's BMRN Position: Q4 2013 in Review

Pier Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2013, closing a stake of 720 shares — an estimated $52K sold.

Pier Capital first reported a position in BMRN in Q2 2013 and held it in 2 quarters. The position peaked at $52K in Q3 2013. 307 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

  • Pier Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Pier Capital sold 720 BioMarin Pharmaceuticals shares in Q4 2013, an estimated $52K.
  • Pier Capital first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Pier Capital's BioMarin Pharmaceuticals position peaked at $52K in Q3 2013.
  • 307 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Pier Capital's 13F filing for Q4 2013, filed 13 Feb 2014.